CTRI/2019/10/021762招募中4 期
Impact of preoperative Zoledronic acid on Bone health indices in patients with primary hyperparathyroidism after curative parathyroidectomy : A randomized controlled trial
试验速览
- 阶段
- 4 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with biochemically proven primary hyperparathyroidism fulfilling criteria to undergo surgery
- •Hypercalcemia ( Calcium levels > 11 mg/dL)
排除标准
- •Renal dysfunction (Creatinine clearance <30 ml/minute)
- •Pregnancy or lactation.
- •Patients who have received any other bisphosphonates or antiresorptive therapy within a year before surgery.
- •Patients developing permanent hypoparathyroidism after surgery
- •Failed surgery
- •Any chronic disease that may affect bone health significantly.
研究者
相似试验
进行中（未招募）
1 期
Zoledronic acid in patients with metastatic prostate cancer treated with abiraterone acetate: impact on bone mineral densityMetastatic castration-resistant prostate cancerMedDRA version: 18.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001146-34-FRCentre Oscar Lambret
进行中（未招募）
不适用
„Effect of intravenous Zoledronic Acid on Bone Metabolism given over 4 month in patients with prostate cancer or breast cancer and bone metastasis. A prospective, single-arm multicenter study” (ZoTect) - ZoTectEUCTR2005-002132-94-DEovartis Pharma GmbH405
招募中
不适用
Effect of Intravenous Zoledronic Acid on Bone Mineral Density in Osteoporosis PatientsDiseases of the musculo-skeletal system and connective tissueKCT0003045Wonkwang University Hospital50
进行中（未招募）
不适用
Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine or endocrine treatment - ProBONE IIEUCTR2004-002832-24-DEovartis Pharma GmbH
进行中（未招募）
不适用
Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor negative breast cancer and adjuvant chemotherapeutic treatment - ProBONE IEUCTR2004-002831-14-DEovartis Pharma GmbH